Updated on 11 February 2013
Sun Pharmaceutical and Taro Pharmaceutical have mutually agreed to terminate their merger agreement
Singapore: Sun Pharmaceutical and Taro Pharmaceutical have mutually agreed to terminate their merger agreement, announced during August 2012, pursuant to which, all shareholders of Taro (other than Sun Pharma and its affiliates) would have received a cash payment of $39.50 per share upon the closing of the merger.
Each of Sun Pharma and Taro have agreed at the direction of the special committee that terminating the merger agreement was in the best interest of the respective companies and shareholders.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
